Table 3. Adverse events.
AEs | N = 90 |
AEs occurring during the study in ≥5% patients, n (%) | |
Headache | 6 (7) |
Nasopharyngitis | 6 (7) |
Nausea | 5 (6) |
Weight decrease | 5 (6) |
Rash | 5 (6) |
Study drug-related adverse events occurring in >1 patient | |
Nausea | 3 (3) |
Creatinine renal clearance decreased | 2 (2) |
Serious adverse events | |
HCC (not related to study drug) | 1 (1) |
AE, adverse event; HCC, hepatocellular carcinoma.